kyv-101
Generic: Autologous Anti-CD19 CAR-CD8alpha-CD28-CD3zeta T Cells KYV 101·Code: KYV-101
kyv-101: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | Phase 2/Phase 3 |
Clinical Trials (1)
KYSA-5: A Phase 1/2, Open-Label, Multicentre Study of KYV 101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis
Frequently asked questions
Who is developing kyv-101?
kyv-101 is being developed by Kyverna Therapeutics, Inc..
How many clinical trials involve kyv-101?
BioSniper tracks 1 clinical trial involving kyv-101.
Get deeper analysis on kyv-101
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis